Safety and efficacy of short-term celecoxib before elective percutaneous coronary intervention for stable angina pectoris.
Fifty patients with stable angina pectoris entered a randomized, double-blind study and were assigned to receive celecoxib (200 mg 2 times daily) or placebo 7 days before percutaneous coronary intervention (PCI). Results showed that detection of markers of myocardial injury above the upper normal limit was significantly lower in the celecoxib than in the placebo group: 12% versus 35% for creatine kinase-MB (CK-MB; p = 0.001), 20% versus 48% for troponin I (p = 0.0004), and 22% versus 51% for myoglobin (p = 0.0005). Myocardial infarction by CK-MB determination was less commonly seen after PCI in the celecoxib than in the placebo group (5% vs 18%, p = 0.025). Postprocedural peak levels of CK-MB (2.9 +/- 18 vs 7.5 +/- 18 ng/ml, p = 0.0002) were also significantly lower in the celecoxib than in the placebo group. No significant side effect was reported by the 2 groups of patients. In conclusion, pretreatment with celecoxib 200 mg 2 times daily for 7 days significantly decreased procedural myocardial injury in elective PCI. These findings indicate that the antiphlogistic action of cyclo-oxygenase-2 inhibition may provide a friendly protection to ischemic cardiomyocytes.
Pelliccia
Francesco
F
Department of Cardiovascular Diseases, San Filippo Neri Hospital, Rome, Italy. f.pelliccia@mclink.it
Pasceri
Vincenzo
V
Granatelli
Antonino
A
Pristipino
Christian
C
Speciale
Giulio
G
Roncella
Adriana
A
Cianfrocca
Cinzia
C
Mercuro
Giuseppe
G
Richichi
Giuseppe
G
D000787:Angina Pectoris / Q000628:therapy*; D015906:Angioplasty, Balloon, Coronary; D015415:Biomarkers / Q000097:blood; D000068579:Celecoxib; D003131:Combined Modality Therapy; D052279:Creatine Kinase, MB Form / Q000097:blood; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D006801:Humans; D009211:Myoglobin / Q000097:blood; D010865:Pilot Projects; D011720:Pyrazoles / Q000008:administration & dosage / Q000627:therapeutic use*; D015607:Stents; D013449:Sulfonamides / Q000008:administration & dosage / Q000627:therapeutic use*; D019210:Troponin I / Q000097:blood
D015415:Biomarkers; D016861:Cyclooxygenase Inhibitors; D009211:Myoglobin; D011720:Pyrazoles; D013449:Sulfonamides; D019210:Troponin I; D052279:Creatine Kinase, MB Form; D000068579:Celecoxib